Literature DB >> 3430190

Muscle pathology in the neuroleptic malignant syndrome.

D T Martin1, M Swash.   

Abstract

In a fatal case of neuroleptic malignant syndrome, a muscle sample taken within 1 h of death showed acute myopathic features with absence of muscle glycogen and neutral lipid. These features suggest that hyperpyrexia in this syndrome may be caused by heat production from uncoupled phosphorylation in muscle and imply that the primary biochemical abnormality responsible for this uncontrolled heat production might be muscular rather than hypothalamic.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3430190     DOI: 10.1007/BF00718024

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  13 in total

Review 1.  Current concepts. Neuroleptic malignant syndrome.

Authors:  B H Guzé; L R Baxter
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

2.  Neuroleptic malignant syndrome and malignant hyperthermia.

Authors:  S Caroff; H Rosenberg; J C Gerber
Journal:  Lancet       Date:  1983-01-29       Impact factor: 79.321

3.  The neuroleptic malignant syndrome.

Authors:  R A Smego; D T Durack
Journal:  Arch Intern Med       Date:  1982-06

4.  Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs.

Authors:  M Toru; O Matsuda; K Makiguchi; K Sugano
Journal:  J Nerv Ment Dis       Date:  1981-05       Impact factor: 2.254

5.  Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease.

Authors:  R E Burke; S Fahn; R Mayeux; H Weinberg; K Louis; J H Willner
Journal:  Neurology       Date:  1981-08       Impact factor: 9.910

6.  Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine.

Authors:  J E Granato; B J Stern; A Ringel; A H Karim; A Krumholz; J Coyle; S Adler
Journal:  Ann Neurol       Date:  1983-07       Impact factor: 10.422

7.  Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases.

Authors:  M Goulon; P de Rohan-Chabot; D Elkharrat; P Gajdos; C Bismuth; F Conso
Journal:  Neurology       Date:  1983-04       Impact factor: 9.910

8.  General anesthesia after neuroleptic malignant syndrome.

Authors:  F Lotstra; P Linkowski; J Mendlewicz
Journal:  Biol Psychiatry       Date:  1983-02       Impact factor: 13.382

9.  Malignant neuroleptic syndrome--its present status in Japan and clinical problems.

Authors:  H Itoh; N Ohtsuka; K Ogita; G Yagi; S Miura; Y Koga
Journal:  Folia Psychiatr Neurol Jpn       Date:  1977

10.  Neuroleptic malignant syndrome.

Authors:  H H Morris; W F McCormick; J A Reinarz
Journal:  Arch Neurol       Date:  1980-07
View more
  4 in total

1.  Muscle changes in the neuroleptic malignant syndrome.

Authors:  W M Behan; M Madigan; B J Clark; J Goldberg; D R McLellan
Journal:  J Clin Pathol       Date:  2000-03       Impact factor: 3.411

2.  Pathology of neuroleptic malignant syndrome.

Authors:  A Bakheit; W M Behan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-03       Impact factor: 10.154

3.  The muscle findings in the neuroleptic malignant syndrome associated with lysergic acid diethylamide.

Authors:  W M Behan; A M Bakheit; P O Behan; I A More
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

4.  Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology.

Authors:  E M Jones; A Dawson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.